Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:FEED

Nanovibronix Q4 2025 Earnings Report

Nanovibronix logo
$0.52 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$0.53 +0.01 (+2.12%)
As of 07/2/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanovibronix EPS Results

Actual EPS
-$20.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$0.31 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Q4 2025
Date
4/15/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanovibronix Earnings Headlines

Brazil Potash Awards Front End Engineering Design (FEED) Contract For Mine Shafts and Underground Development to WSP UK Ltd., with Redpath Deilmann Mining Inc. as Subconsultants, Completing Full-Project FEED Coverage at Autazes
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313300/0/en/brazil-potash-awards-front-end-engineering-design-feed-contract-for-mine-shafts-and-underground-development-to-wsp-uk-ltd-with-redpath-deilmann-mining-inc-as-subconsultants-complet.html
Ohmium and Hynfra Sign Master Cooperation Agreement to Advance Large-Scale Green Hydrogen Projects in the Middle East and Africa
June 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260617825133/en/ohmium-and-hynfra-sign-master-cooperation-agreement-to-advance-large-scale-green-hydrogen-projects-in-the-middle-east-and-africa/
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.tc pixel
July 5 at 1:00 AM  |  Weiss Ratings (Ad)
ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308809/0/en/envue-medical-launches-ai-training-platform-establishing-artificial-intelligence-foundation-for-robotic-feeding-tube-navigation.html
ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
June 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/05/3307384/0/en/envue-medical-expands-into-burn-intensive-care-unit-at-major-academic-health-network.html
ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3306023/0/en/envue-medical-announces-publication-of-landmark-independent-study-highlighting-significant-safety-time-and-cost-saving-benefits-of-envue-navigation-platform-in-multi-hospital-syste.html
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:FEED) (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves.

As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.

View Nanovibronix Profile
Earnings Tools